NAVB
Navidea Biopharmaceuticals Inc.
NAVB
NAVB
Delisted
NAVB was delisted on the 5th of October, 2023.
26 hedge funds and large institutions have $1.08M invested in Navidea Biopharmaceuticals Inc. in 2022 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 4 increasing their positions, 5 reducing their positions, and 3 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
less capital invested
Capital invested by funds: $ → $
less repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
83% less call options, than puts
Call options by funds: $39K | Put options by funds: $233K
Holders
26
Holding in Top 10
–
Calls
$39K
Puts
$233K
Top Buyers
| 1 | +$18K | |
| 2 | +$10K | |
| 3 | +$9K | |
| 4 |
PP
PDS Planning
Dublin,
Ohio
|
+$8K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$5.31K |
Top Sellers
| 1 | -$38.3K | |
| 2 | -$11K | |
| 3 | -$10.4K | |
| 4 |
Two Sigma Advisers
New York
|
-$9K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$1.33K |